Category: biotech

.After a handful of years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma layer, occupying the best science place at Sanofi.Quigley is

.Sanofi has actually created an overdue access to the radioligand event, paying for one hundred million euros ($ 110 thousand) in advance for international legal

.Sanofi has actually quit a stage 2 ordeal of Denali Therapeutics-partnered oditrasertib in various sclerosis. The French drugmaker tore the RIPK1 prevention difficulty coming from

.Sangamo Therapeutics has actually determined a quick way to market for its own Fabry ailment applicant, aligning along with the FDA on a pathway that

.Sage Rehabs’ most up-to-date try to shrink its pipeline as well as labor force will definitely see a 3rd of the biotech’s workers going to

.Matt Gline is back along with a new ‘vant’ provider, after the Roivant Sciences chief executive officer paid for Bayer $14 million upfront for the

.Roche has actually returned the legal rights to UCB’s anti-tau antitoxin bepranemab, walking away from a $120 thousand bet on the Alzheimer’s disease medication candidate

.Roche is keeping out chances that its injectable being overweight prospect could eventually show 25% weight loss in late-stage trials, the pharma’s head of metabolic

.Roche’s severe cough program has faltered to a stop. The drugmaker, which axed the system after the medicine candidate let down in phase 2, divulged

.After creating a gene therapy relationship with Dyno Rehabs in 2020, Roche is back for additional.In a new package potentially worth greater than $1 billion,